×

Tranquis Therapeutics – TQS-168

Redwood, California-based Tranquis Therapeutics, is a clinical-stage biopharmaceutical company that is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. Their therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a more functional state by targeting master regulators of cell energy metabolism, such as PGC1α. Tranquis’s lead product is TQS-168, which is currently in Phase one of clinical trials is being developed a a treatment for amyotrophic lateral sclerosis (ALS). TQS -168 has shown benefits in various animal models of neurodegenerative disease, including ALS. In vitro, TQS-168 also shows specific immunomodulatory effects in cell lines and white blood cells from patients with ALS and may therefore have other indications.

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2025 Lifespan Research Institute – ALL RIGHTS RESERVED